Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Net Income (2022 - 2025)

Zentalis Pharmaceuticals has reported Net Income over the past 4 years, most recently at -$35.2 million for Q4 2025.

  • Quarterly results put Net Income at -$35.2 million for Q4 2025, up 25.82% from a year ago — trailing twelve months through Dec 2025 was -$137.1 million (up 17.37% YoY), and the annual figure for FY2025 was -$137.1 million, up 17.37%.
  • Net Income for Q4 2025 was -$35.2 million at Zentalis Pharmaceuticals, down from -$26.7 million in the prior quarter.
  • Over the last five years, Net Income for ZNTL hit a ceiling of $10.0 million in Q1 2024 and a floor of -$98.9 million in Q2 2023.
  • Median Net Income over the past 4 years was -$50.2 million (2022), compared with a mean of -$50.0 million.
  • Biggest five-year swings in Net Income: skyrocketed 116.47% in 2024 and later tumbled 580.87% in 2025.
  • Zentalis Pharmaceuticals' Net Income stood at -$48.2 million in 2022, then fell by 26.53% to -$60.9 million in 2023, then increased by 22.1% to -$47.5 million in 2024, then grew by 25.82% to -$35.2 million in 2025.
  • The last three reported values for Net Income were -$35.2 million (Q4 2025), -$26.7 million (Q3 2025), and -$26.9 million (Q2 2025) per Business Quant data.